Blog Category

admin

Biophytis announces the drawing of 2 new tranches of ORNANE under the 2020 Atlas Contract for €6 million

/

4 October 2021

Biophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021

/

4 October 2021

Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021

,

/

29 September 2021

SEPTEMBER 21, 2021

/

21 September 2021

Biophytis publishes its interim financial report for the first half of 2021 and provides updates on key operational developments and financing transactions

, , ,

/

17 September 2021

Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19

,

/

15 September 2021

Biophytis to attend key upcoming investor events and industry conferences

,

/

14 September 2021

ICFSR 2021 – International Conference on Frailty & Sarcopenia Research

,

/

10 September 2021

Biophytis leadership is reinforced with new Chief Medical Officer appointment

,

/

9 September 2021

Biophytis receives favorable recommendation from Data Monitoring Committee (DMC) based on safety analysis of Sarconeos (BIO101) to continue patients recruitment in the COVA study in COVID-19

/

16 August 2021

Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021

/

13 August 2021

AUGUST 12, 2021

/

12 August 2021